Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …

A differentiation block and an accumulation of immature myeloid cells characterize acute
myelogenous leukemia (AML). However, native AML cells usually show some …

Acute myeloid leukemia (AML) is the most aggressive adult leukemia, characterized by
clonal differentiation arrest of progenitor or precursor hematopoietic cells. Intense preclinical …

Acute myeloid leukaemia (AML) is a malignant disorder of the myeloid blood lineage
characterized by impaired differentiation and increased proliferation of hematopoietic …

Over the last three decades there have been dramatic advances in deciphering the
cytogenetic and molecular lesions underlying the pathogenesis of acute myeloid leukemia …

Despite rapid advances in our understanding of acute myeloid leukemia (AML), the disease
remains challenging to treat with 5-year survival for adult patients 20 years or older …

Acute myeloid leukemia (AML) is an intrinsically resistant disease. Prognosis is poor for the
majority of AML patients, based on age and/or adverse biologic features. Standard therapy …

Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) each represent a
heterogeneous complex of disorders, which result from diverse mechanisms of …

BACKGROUND AND OBJECTIVE: The successful use of differentiating treatment for
patients with acute promyelocytic leukemia (APL) suggests that other acute myeloid …

Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically
heterogeneous disease, and its incidence is increasing as the population ages …